Manfred Wozny

Title: Manfred Wozny: Innovator in Biopharmaceuticals

Introduction

Manfred Wozny is a notable inventor based in Weilheim, Germany. He has made significant contributions to the field of biopharmaceuticals, particularly through his innovative patents. With a total of two patents to his name, Wozny's work focuses on enhancing the efficacy of therapeutic proteins.

Latest Patents

Wozny's latest patents include "Erythropoietin conjugates," which refers to conjugates of erythropoietin with poly(ethylene glycol). This invention involves an erythropoietin glycoprotein that has an N-terminal α-amino group and retains the in vivo biological activity of stimulating bone marrow cells to increase the production of reticulocytes and red blood cells. The glycoprotein is covalently linked to a poly(ethylene glycol) group, forming an amide bond with the N-terminal α-amino group. Another significant patent is related to a mutant of the Erythrina caffra type inhibitor, which selectively binds serine proteases. This polypeptide is produced by culturing transformed host cells and is particularly useful for purifying tissue plasminogen activators.

Career Highlights

Throughout his career, Wozny has worked with prominent companies in the pharmaceutical industry. He has been associated with Hoffmann-La Roche Inc. and Roche Diagnostics GmbH, where he contributed to various innovative projects. His expertise in biopharmaceuticals has positioned him as a valuable asset in the field.

Collaborations

Wozny has collaborated with notable colleagues, including Josef Burg and Alfred Engel. These partnerships have fostered a collaborative environment that has led to advancements in their respective fields.

Conclusion

Manfred Wozny's contributions to biopharmaceuticals through his patents and collaborations highlight his innovative spirit and dedication to improving therapeutic solutions. His work continues to influence the industry and pave the way for future advancements.